论文部分内容阅读
恶性黑色素瘤(MM)预后评估最为普遍接受的标准是组织病理和临床表现。尚无现代有效实验测试可提供附加预后信息。新近提出采用逆转录多聚酶链反应(RT-PCR)检测外周血酪氨酸酶信使RNA(mRNA)早期检出循环的肿瘤细胞。酪氨酸酶被认为是黑色素细胞特异的标记物,为进一步评估这一潜在标记物的临床相关性,作者在MM病人的不同病期外周血标本检查酪氨酸酶mRNA。 采用RNAzol A方法,从64例MM病人、5例健康者、4例其它癌病人的肝素化外周血细胞提取总细胞
The most commonly accepted criteria for evaluating the prognosis of malignant melanoma (MM) are histopathology and clinical manifestations. There are no modern effective experimental tests that provide additional prognostic information. Recently, it has been proposed to use reverse transcription polymerase chain reaction (RT-PCR) to detect tyrosinase messenger RNA (mRNA) in peripheral blood to detect circulating tumor cells at an early stage. Tyrosinase is considered to be a melanocyte-specific marker. To further evaluate the clinical relevance of this potential marker, the authors examined tyrosinase mRNA in peripheral blood samples of patients with MM. Total RNA extracted from heparinized peripheral blood cells from 64 MM patients, 5 healthy subjects, and 4 other cancer patients using RNAzol A method